| DRUG WATCH |
|
| Year : 2013 | Volume
: 45
| Issue : 2 | Page : 191-192 |
Tenofovir induced Fanconi syndrome: A possible pharmacokinetic interaction
Jigar Kapadia1, Samidh Shah1, Chetna Desai1, Mira Desai1, Shivani Patel2, Asha N Shah3, RK Dikshit1
1 Department of Pharmacology, B. J. Medical College, Ahmedabad, India
2 Department of Medicine, B. J. Medical College, Ahmedabad, India
3 Department of Medicine and Nodal Officer, ART Center, Civil Hospital, Ahmedabad, India
Correspondence Address:
Samidh Shah
Department of Pharmacology, B. J. Medical College, Ahmedabad
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.108319
Tenofovir was introduced as a second line drug for the treatment of human immunodeficiency virus (HIV) infection in India in December 2009. Although rare, renal toxicity is a recognized adverse drug reaction (ADR) of this drug, especially when administered with boosted lopinavir-ritonavir. In this case, an HIV positive patient receiving tenofovir based antiretroviral therapy (ART) for last 1 year developed albuminuria, glycosuria and hypophosphatemia. Renal function tests and random blood sugar were within normal limits. He was diagnosed as a case of tenofovir induced Fanconi syndrome. Tenofovir was discontinued and patient was prescribed an alternate regimen. Five months later clinical symptoms and renal functions returned to normal. A pharmacokinetic interaction between tenofovir and ritonavir may have resulted in the toxicity. A periodic monitoring of renal functions is desirable in patients on tenofovir based ART.
[FULL TEXT] [PDF]*
|
